drugset / Trial / NCT03474133
Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)
Phase 2
Unknown
80 enrolled
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NaSingle-groupOpen-labelTreatment
Summary
This study evaluate possibility of brentuximab vedotin, administered after first treatment failure (no response or relapse after I line therapy) of Hodgkin's lymphoma, to induce durable response or cure without autologous stem cell transplantation.
Timeline
- Start
- 2019-05-14
- Primary completion
- 2023-10-01
- Completion
- 2023-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | Intravenous |